2910 Seventh Street
United States - Map
XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company offers ACEON, an angiotensin converting enzyme inhibitor. Its proprietary products include gevokizumab, a human engineering (HE) antibody to interleukin-1 beta, which is Phase III studies for non-infectious uveitis and Behçets uveitis; and Phase II studies for inflammatory acne, erosive osteoarthritis of the hand, active non-infectious anterior scleritis, and cardiovascular diseases. The companys proprietary products also comprise XOMA metabolic activating, sensitizing, and antagonizing/deactivating antibodies that are in preclinical stage for diabetes, metabolic disorders, and other orphan indications; XOMA 3AB, a multi-antibody product, which is in Phase I trial for botulism poisoning; and preclinical programs for autoimmune, cardio-metabolic, infectious, inflammatory, ophthalmological, and oncological diseases. In addition, it develops FDC1, a perindopril arginine and amlodipine besylate, which has completed Phase III trial for hypertension; HCD122 and LFA102 programs that are in Phase I and II, and Phase I trials for hematologic tumors, breast and prostate cancers, and other undisclosed diseases; human monoclonal antibodies, which are in preclinical stage for undisclosed disease targets; and therapeutic antibodies that are in Phase II and Phase I trials for non-small cell lung cancer, solid tumors, and multiple myeloma. Further, the company licenses Antibody Discovery Advanced Platform Technologies, ModulX, and OptimX antibody discovery, optimization, and development technologies. It has collaboration agreements with Les Laboratoires Servier; National Institute of Allergy and Infectious Diseases; Takeda Pharmaceutical Company Limited; Novartis AG; Arana Therapeutics Limited; Kaketsuken; AVEO Pharmaceuticals, Inc.; UCB Celltech; and Genentech, Inc. XOMA Corporation was founded in 1981 and is headquartered in Berkeley, California.
|XOMA Corporation’s ISS Governance QuickScore as of Mar 1, 2014 is 8. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 2; Compensation: 10.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. John W. Varian ,
Chief Exec. Officer and Independent Director
|Mr. Patrick J. Scannon M.D., Ph.D.,
Founder, Chief Scientific Officer, Exec. VP and Director
|Mr. Fred Kurland ,
Chief Financial Officer, Principal Accounting Officer, VP of Fin. and Sec.
|Mr. Paul D. Rubin M.D.,
Chief Medical Officer and Sr. VP of Clinical Devel.
|Mr. Charles C. Wells ,
VP of HR & Information Technology
|Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|